Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Age-specific occurrence of HPV16- and HPV18-related cervical cancer.

de Sanjose S, Wheeler CM, Quint WG, Hunt WC, Joste NE, Alemany L, Xavier Bosch F; Retrospective International Survey and HPV Time Trends Study Group, Myers ER, Castle PE.

Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1313-8. doi: 10.1158/1055-9965.EPI-13-0053. Epub 2013 Apr 30.

2.

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.

Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE.

J Natl Cancer Inst. 2009 Apr 1;101(7):475-87. doi: 10.1093/jnci/djn510. Epub 2009 Mar 24.

3.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
4.

Prevalence and genotyping of high risk human papillomavirus in cervical cancer samples from Punjab, Pakistan.

Siddiqa A, Zainab M, Qadri I, Bhatti MF, Parish JL.

Viruses. 2014 Jul 17;6(7):2762-77. doi: 10.3390/v6072762.

5.

Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand.

Kang YJ, Lewis H, Smith MA, Simonella L, Neal H, Bromhead C, Canfell K.

BMC Infect Dis. 2015 Aug 22;15:365. doi: 10.1186/s12879-015-1034-5.

6.

Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.

Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK.

PLoS One. 2014 Feb 5;9(2):e88323. doi: 10.1371/journal.pone.0088323. eCollection 2014.

7.

Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.

Coutlée F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N, Ghatage P, Koushik A, Ferenczy A, Franco EL.

J Med Virol. 2011 Jun;83(6):1034-41. doi: 10.1002/jmv.22081.

PMID:
21503917
8.

Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer.

Arnheim Dahlström L, Andersson K, Luostarinen T, Thoresen S, Ögmundsdottír H, Tryggvadottír L, Wiklund F, Skare GB, Eklund C, Sjölin K, Jellum E, Koskela P, Wadell G, Lehtinen M, Dillner J.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2541-50. doi: 10.1158/1055-9965.EPI-11-0761. Epub 2011 Oct 12.

9.

Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18.

Xi LF, Koutsky LA, Hildesheim A, Galloway DA, Wheeler CM, Winer RL, Ho J, Kiviat NB.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):4-10.

10.

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Kjær SK, Frederiksen K, Munk C, Iftner T.

J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88. doi: 10.1093/jnci/djq356. Epub 2010 Sep 14.

11.

Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.

Simonella LM, Lewis H, Smith M, Neal H, Bromhead C, Canfell K.

BMC Infect Dis. 2013 Mar 3;13:114. doi: 10.1186/1471-2334-13-114.

12.

Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.

Velentzis LS, Sitas F, O'Connell DL, Darlington-Brown J, Egger S, Sinha R, Banks E, Frazer IH, Canfell K.

BMC Infect Dis. 2014 Dec 21;14:3861. doi: 10.1186/s12879-014-0676-z.

13.

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.

14.

Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species.

Xi LF, Edelstein ZR, Meyers C, Ho J, Cherne SL, Schiffman M.

Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2507-12. doi: 10.1158/1055-9965.EPI-09-0482. Epub 2009 Aug 18.

15.

How much cervical cancer in Australia is vaccine preventable? A meta-analysis.

Brotherton JM.

Vaccine. 2008 Jan 10;26(2):250-6. Epub 2007 Nov 20.

PMID:
18068276
16.

Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer.

Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, Ochi H, Nakao S, Someya K, Yamada N, Hamada H, Yoshikawa H.

Cancer Sci. 2009 Jul;100(7):1312-6. doi: 10.1111/j.1349-7006.2009.01161.x. Epub 2009 Apr 22.

17.

Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK).

Powell N, Cuschieri K, Cubie H, Hibbitts S, Rosillon D, De Souza SC, Molijn A, Quint W, Holl K, Fiander A.

J Clin Virol. 2013 Nov;58(3):571-4. doi: 10.1016/j.jcv.2013.08.020. Epub 2013 Aug 30.

PMID:
24051043
18.

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group.

Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15.

PMID:
20952254
19.

Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?

Kjær SK, Munk C, Junge J, Iftner T.

Cancer Causes Control. 2014 Feb;25(2):179-89. doi: 10.1007/s10552-013-0320-z. Epub 2013 Nov 17.

PMID:
24242002
20.

A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, Robertson M, Shearman CA, Castle PE; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2013 Jan 1;132(1):198-207. doi: 10.1002/ijc.27608. Epub 2012 Jun 20.

Items per page

Supplemental Content

Write to the Help Desk